Cyclophosphamide

Form: Oral Tablet & Injection:

Strength: Injection: 200 mg/2 mL (vial), 500 mg/5 mL (vial); Tablet: 25 mg, 50 mg ,100 mg

Reference Brands: Cytoxan®(US & EU), Endoxan®(EU)

Category: Oncology Cancer Care

Cyclophosphamide, marketed as Cytoxan® (US) and Endoxan® (EU), is a chemotherapy agent widely used in the treatment of cancers such as breast cancer, ovarian cancer, non-Hodgkin lymphoma, leukemia, and multiple myeloma. Additionally, it is used in the treatment of autoimmune diseases, including systemic lupus erythematosus. Available in IV infusion (200 mg/2 mL, 500 mg/5 mL) and oral tablet (25 mg, 50 mg, 100 mg) forms, Cyclophosphamide works as an alkylating agent to disrupt cancer cell DNA, offering significant opportunities for B2B oncology pharmaceutical companies in the US and EU markets.